Abrahim Al-Mamgani
Research Subjects
Abrahim Al-Mamgani has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Peter C. Levendag
Department of Radiation Oncology-Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
12 shared publicationsLisa Tans
9 shared publicationsPeter van Rooij
Department of Biostatistics Erasmus Medical Center – Daniel den Hoed Cancer Center Rotterdam The Netherlands
9 shared publicationsAniel Sewnaik
5 shared publicationsGerda M. Verduijn
5 shared publicationsJoos V. Lebesque
4 shared publications
Latest Publications
- 1 October 2013
- Published by Elsevier in Oral Oncology
- Vol. 49 (10) , 1018-1024
Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: Comparable outcomes of two different approaches
- 1 October 2013
- Published by Elsevier in Oral Oncology
- Vol. 49 (10) , 1018-1024
Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: Comparable outcomes of two different approaches
- 20 August 2013
- Published by Wiley in Clinical Otolaryngology
- Vol. 38 (4) , 306-312
Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients
Objectives: To evaluate the outcomes of patients with early stage glottic cancer (GC) treated with radiotherapy (RT).Design, setting and participants: The current study report on a retrospective analysis of oncologic outcome of 1050 patients with T1‐2N0 glottic cancer treated with radiotherapy. Prospective assessment of quality of life (QoL) and voice handicap index (VHI) was performed in all patients treated from 2006 onwards (n = 233).Main outcome measures: Local control (LC), regional control (RC), disease‐free survival (DFS), overall survival (OS), quality of life and voice handicap index.Results: After a median follow‐up of 90 months (range 3–309), the actuarial rates of local control, regional control, disease‐free survival and overall survival were 85%, 99%, 84% and 81% at 5 years and 82%, 98%, 80% and 61% at 10 years, respectively. On multivariate analysis, T2 tumours, smoking after radiotherapy and conventional radiation scheme correlated significantly with poor local control. Patients who continued smoking after radiotherapy had also significantly lower overall survival rates (OR 4.3, P < 0.001). Hypothyroidism was reported in 18% of patients. Slight and temporary deterioration of quality of life scores was reported. Patient‐reported xerostomia and dysphagia at 48 months were −7.1 and −6.5, compared with baseline, respectively. Voice handicap index improved significantly from 37 at baseline to 18 at 48 months. Patients with T2b and those who continued smoking had significantly worse voice handicap index.Conclusions: In the current study, excellent outcome with good quality of life and voice handicap index scores were reported. T2 tumours, in particular T2b, and continuing smoking after radiotherapy correlated significantly with poor local control and worse voice handicap index.
- 20 August 2013
- Published by Wiley in Clinical Otolaryngology
- Vol. 38 (4) , 306-312
Radiotherapy for T1‐2N0 glottic cancer: a multivariate analysis of predictive factors for the long‐term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients
Objectives: To evaluate the outcomes of patients with early stage glottic cancer (GC) treated with radiotherapy (RT).Design, setting and participants: The current study report on a retrospective analysis of oncologic outcome of 1050 patients with T1‐2N0 glottic cancer treated with radiotherapy. Prospective assessment of quality of life (QoL) and voice handicap index (VHI) was performed in all patients treated from 2006 onwards (n = 233).Main outcome measures: Local control (LC), regional control (RC), disease‐free survival (DFS), overall survival (OS), quality of life and voice handicap index.Results: After a median follow‐up of 90 months (range 3–309), the actuarial rates of local control, regional control, disease‐free survival and overall survival were 85%, 99%, 84% and 81% at 5 years and 82%, 98%, 80% and 61% at 10 years, respectively. On multivariate analysis, T2 tumours, smoking after radiotherapy and conventional radiation scheme correlated significantly with poor local control. Patients who continued smoking after radiotherapy had also significantly lower overall survival rates (OR 4.3, P < 0.001). Hypothyroidism was reported in 18% of patients. Slight and temporary deterioration of quality of life scores was reported. Patient‐reported xerostomia and dysphagia at 48 months were −7.1 and −6.5, compared with baseline, respectively. Voice handicap index improved significantly from 37 at baseline to 18 at 48 months. Patients with T2b and those who continued smoking had significantly worse voice handicap index.Conclusions: In the current study, excellent outcome with good quality of life and voice handicap index scores were reported. T2 tumours, in particular T2b, and continuing smoking after radiotherapy correlated significantly with poor local control and worse voice handicap index.
- 25 June 2013
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 271 (1) , 125-132
Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy
The objective of the presented study is to report on retrospectively collected data on long-term outcome and toxicity and prospective assessment of quality of life (QoL) and Voice-Handicap Index (VHI) of patients with T1a glottic cancer treated with radiotherapy. Between 1985 and 2011, 549 patients were treated. Endpoints were local control (LC), toxicity, QoL and VHI. After a median follow-up of 93 months, the actuarial rates of LC were 91, and 90 % at 5- and 10-years, respectively. Continuing smoking (p < 0.001) and anaemia (p = 0.02) were significantly correlated with poor LC on univariate analysis and fractionation schedule did not show significant correlation (p = 0.08). On multivariate analysis, only continuing smoking retained significance (p = 0.001). These patients had also significantly increased incidence of second primary tumour and lower overall survival rates. The incidence of grade ≥2 late xerostomia and dysphagia were 10 and 6 %, respectively. Slight and temporary deterioration of QoL-scores was reported. The scores on the EROTC-QOL-H&N35 dysphagia and xerostomia at 24 months were -2 and -3, compared to baseline, respectively. VHI improved significantly from 34 at baseline to 21 at 24 months. Patients who continued smoking had significantly worse VHI. In conclusion, excellent outcome with good QoL and VHI were reported. Patients who continued smoking after radiotherapy had significantly poor LC and worse VHI. The current study emphasizes the importance of smoking cessation and the non-inferiority of hypofractionated schemes in terms of outcome and VHI. At our institution, phase II study is going to evaluate the role of single vocal cord irradiation with high fraction dose.
- 25 June 2013
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 271 (1) , 125-132
Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy
The objective of the presented study is to report on retrospectively collected data on long-term outcome and toxicity and prospective assessment of quality of life (QoL) and Voice-Handicap Index (VHI) of patients with T1a glottic cancer treated with radiotherapy. Between 1985 and 2011, 549 patients were treated. Endpoints were local control (LC), toxicity, QoL and VHI. After a median follow-up of 93 months, the actuarial rates of LC were 91, and 90 % at 5- and 10-years, respectively. Continuing smoking (p < 0.001) and anaemia (p = 0.02) were significantly correlated with poor LC on univariate analysis and fractionation schedule did not show significant correlation (p = 0.08). On multivariate analysis, only continuing smoking retained significance (p = 0.001). These patients had also significantly increased incidence of second primary tumour and lower overall survival rates. The incidence of grade ≥2 late xerostomia and dysphagia were 10 and 6 %, respectively. Slight and temporary deterioration of QoL-scores was reported. The scores on the EROTC-QOL-H&N35 dysphagia and xerostomia at 24 months were -2 and -3, compared to baseline, respectively. VHI improved significantly from 34 at baseline to 21 at 24 months. Patients who continued smoking had significantly worse VHI. In conclusion, excellent outcome with good QoL and VHI were reported. Patients who continued smoking after radiotherapy had significantly poor LC and worse VHI. The current study emphasizes the importance of smoking cessation and the non-inferiority of hypofractionated schemes in terms of outcome and VHI. At our institution, phase II study is going to evaluate the role of single vocal cord irradiation with high fraction dose.
- Open Access
- 1 April 2013
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 12 (2) , 123-130
Toxicity and Outcome of Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy for Oropharyngeal Cancer: A Matched-Pair Analysis
Because of the scarcity of randomized trials comparing toxicity and outcomes of intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer (OPC) with 3D-conformal radiotherapy (3DCRT), we performed a matched-pair analysis from prospectively collected data from the Head and Neck Tumor Registry of our institution. In the absence of phase III trials, we believe this approach provides the highest quality data possible. Ninety-two patients treated with 3DCRT were matched (1:1) to 92 patients treated with IMRT for 9 potential predictive factors for toxicity and outcome: gender, age, T-stage, N-stage, tumor subsite, unilateral neck irradiation, chemotherapy, neck dissection and boost technique. Groups were compared for acute and late toxicity, locoregional control (LRC), disease-free survival (DFS), and overall survival (OS). Oncologic outcomes were estimated using Kaplan-Meier analyses and toxicity was analyzed according to Common Terminology Criteria for Adverse Events v3.0. The overall incidence of grade 3 acute toxicity was significantly reduced by IMRT, compared to 3DCRT (45% vs. 70%, p = 0.001). The need for tube feeding was reduced from 50% to 37% ( p = 0.04). The 3-year actuarial incidence of grade ≥2 late toxicity was also significantly reduced by IMRT, compared to 3DCRT (20% vs. 45%, respectively; p < 0.0001). The incidence of grade ≥2 late dysphagia and xerostomia for IMRT vs. 3DCRT were 10% vs. 31% for dysphagia, p = 0.004 and 13% vs. 37%, for xerostomia, respectively ( p = 0.001). The 3-year Kaplan-Meier estimates of LRC, DFS, and OS for IMRT vs. 3DCRT were 90% vs. 82% ( p = 0.1), 82% vs. 76% ( p = 0.3), and 72% vs. 64% ( p = 0.2), respectively. In conclusion, the presented nonrandomized comparative study of well-matched groups demonstrates the superiority of IMRT vs. 3DCRT for OPC by significantly reducing radiation-induced toxicity without jeopardizing outcomes. The improved therapeutic ratio achieved by the use of IMRT would allow dose escalation of radiotherapy to further improve outcomes of patients with OPC.
- 1 April 2013
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 12 (2) , 123-130
Open AccessToxicity and Outcome of Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy for Oropharyngeal Cancer: A Matched-Pair Analysis
Because of the scarcity of randomized trials comparing toxicity and outcomes of intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer (OPC) with 3D-conformal radiotherapy (3DCRT), we performed a matched-pair analysis from prospectively collected data from the Head and Neck Tumor Registry of our institution. In the absence of phase III trials, we believe this approach provides the highest quality data possible. Ninety-two patients treated with 3DCRT were matched (1:1) to 92 patients treated with IMRT for 9 potential predictive factors for toxicity and outcome: gender, age, T-stage, N-stage, tumor subsite, unilateral neck irradiation, chemotherapy, neck dissection and boost technique. Groups were compared for acute and late toxicity, locoregional control (LRC), disease-free survival (DFS), and overall survival (OS). Oncologic outcomes were estimated using Kaplan-Meier analyses and toxicity was analyzed according to Common Terminology Criteria for Adverse Events v3.0. The overall incidence of grade 3 acute toxicity was significantly reduced by IMRT, compared to 3DCRT (45% vs. 70%, p = 0.001). The need for tube feeding was reduced from 50% to 37% ( p = 0.04). The 3-year actuarial incidence of grade ≥2 late toxicity was also significantly reduced by IMRT, compared to 3DCRT (20% vs. 45%, respectively; p < 0.0001). The incidence of grade ≥2 late dysphagia and xerostomia for IMRT vs. 3DCRT were 10% vs. 31% for dysphagia, p = 0.004 and 13% vs. 37%, for xerostomia, respectively ( p = 0.001). The 3-year Kaplan-Meier estimates of LRC, DFS, and OS for IMRT vs. 3DCRT were 90% vs. 82% ( p = 0.1), 82% vs. 76% ( p = 0.3), and 72% vs. 64% ( p = 0.2), respectively. In conclusion, the presented nonrandomized comparative study of well-matched groups demonstrates the superiority of IMRT vs. 3DCRT for OPC by significantly reducing radiation-induced toxicity without jeopardizing outcomes. The improved therapeutic ratio achieved by the use of IMRT would allow dose escalation of radiotherapy to further improve outcomes of patients with OPC.
- 9 March 2013
- Published by Wiley in Head & Neck
- Vol. 35 (12) , 1689-1697
Intensity‐modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer
Background: The purpose of this study was to reduce the incidence of radiation‐induced toxicity in patients with early‐stage oropharyngeal cancer, using highly conformal radiation techniques.Methods: Between 2000 and 2011, 167 patients with T1‐3N0‐3 oropharyngeal cancer were treated with 46‐Gy intensity‐modulated radiation therapy (IMRT) followed by 22‐Gy brachytherapy boost. In patients with node‐positive disease, neck dissection was performed.Results: The 5‐year Kaplan–Meier estimates of local control, regional control, disease‐free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia.Conclusion: Brachytherapy boost and neck dissection (in node‐positive oropharyngeal cancer) after 46‐Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1689–1697, 2012
- 9 March 2013
- Published by Wiley in Head & Neck
- Vol. 35 (12) , 1689-1697
Intensity‐modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer
Background: The purpose of this study was to reduce the incidence of radiation‐induced toxicity in patients with early‐stage oropharyngeal cancer, using highly conformal radiation techniques.Methods: Between 2000 and 2011, 167 patients with T1‐3N0‐3 oropharyngeal cancer were treated with 46‐Gy intensity‐modulated radiation therapy (IMRT) followed by 22‐Gy brachytherapy boost. In patients with node‐positive disease, neck dissection was performed.Results: The 5‐year Kaplan–Meier estimates of local control, regional control, disease‐free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia.Conclusion: Brachytherapy boost and neck dissection (in node‐positive oropharyngeal cancer) after 46‐Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1689–1697, 2012
- 1 January 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106 (1) , 69-73
Unilateral neck irradiation for well-lateralized oropharyngeal cancer
- 1 January 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106 (1) , 69-73
Unilateral neck irradiation for well-lateralized oropharyngeal cancer
- 1 September 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (9) , 905-911
Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation
- 1 September 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (9) , 905-911
Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1278-1286
Node‐positive hypopharyngeal cancer treated by (chemo)radiotherapy: Impact of up‐front neck dissection on outcome, toxicity, and quality of life
Background To investigate the impact of up‐front neck dissection on the outcome of patients with node‐positive hypopharyngeal cancer (HPC) treated with (chemo)radiation. Methods Of 135 consecutive patients with node‐positive HPC, 32 patients underwent up‐front neck dissection followed by (chemo)radiation (group 1), and 103 patients received definitive (chemo)radiation (group 2). Results The 3‐year regional, local and distant control for groups 1 and 2 were 92% versus 87% (p = .37), 84% versus 72% (p = .15), and 80% versus 62% (p = .08), respectively. High T classification was the only significant predictor for poor overall survival on multivariate analysis (OR = 3.0, p = .02). Acute and late toxicities and the prospectively assessed quality of life were comparable in both groups. Conclusion Upfront neck dissection followed by (chemo)radiation did not negatively impact on oncologic outcomes, toxicity, or quality of life and therefore is to be regarded as a safe and effective treatment option for small HPC with bulky nodal disease, especially in busy radiation departments with unacceptably long waiting time for definitive (chemo)radiation. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
- 21 August 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1278-1286
Node‐positive hypopharyngeal cancer treated by (chemo)radiotherapy: Impact of up‐front neck dissection on outcome, toxicity, and quality of life
Background To investigate the impact of up‐front neck dissection on the outcome of patients with node‐positive hypopharyngeal cancer (HPC) treated with (chemo)radiation. Methods Of 135 consecutive patients with node‐positive HPC, 32 patients underwent up‐front neck dissection followed by (chemo)radiation (group 1), and 103 patients received definitive (chemo)radiation (group 2). Results The 3‐year regional, local and distant control for groups 1 and 2 were 92% versus 87% (p = .37), 84% versus 72% (p = .15), and 80% versus 62% (p = .08), respectively. High T classification was the only significant predictor for poor overall survival on multivariate analysis (OR = 3.0, p = .02). Acute and late toxicities and the prospectively assessed quality of life were comparable in both groups. Conclusion Upfront neck dissection followed by (chemo)radiation did not negatively impact on oncologic outcomes, toxicity, or quality of life and therefore is to be regarded as a safe and effective treatment option for small HPC with bulky nodal disease, especially in busy radiation departments with unacceptably long waiting time for definitive (chemo)radiation. © 2012 Wiley Periodicals, Inc. Head Neck, 2013